Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Chronic Obstructive Pulmonary Disease (COPD)

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Virginia Commonwealth University
• Collaborator: American Heart Association

Criteria

Inclusion Criteria:

• Clinically diagnosed of COPD

• Global Initiative for obstructive lung disease (GOLD) Stages II to IV

Exclusion Criteria:

• Forced Expiratory Volume in 1 second/ Functional Vital Capacity (FEV1/FVC) >0.7

• Heart Disease

• Diabetes

• Vasoactive medications

• Uncontrolled high blood pressure

• Fluid in lungs

• Sleep apnea

• Raynaud's Phenomenon

• Gangrene of the digits

• History of coagulation

• Pregnant women

• Children